Freeline
Spur Therapeutics (formerly Freeline) is a clinical-stage UK biotech developing AAV-based single-dose gene therapies, with lead candidate FLT201 in Phase 3 for Gaucher disease type 1 and a pipeline extending into Parkinson's and other chronic conditions. The company is pre-revenue, targeting rare-disease and neurodegenerative patients upon regulatory approval.
- Company typePrivate
- Founded2015
- HeadquartersStevenage, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Freeline does
Freeline Therapeutics, now operating as Spur Therapeutics, is a clinical-stage biotechnology company headquartered in Stevenage, United Kingdom, founded in 2015. The company is developing adeno-associated virus (AAV)-based gene therapies designed to deliver functional genes via single-dose administration, with a stated engineering focus on optimizing gene expression, vector packaging, and delivery to target tissues. Its lead candidate, avigbagene parvec (FLT201), is an investigational AAV gene therapy for Gaucher disease type 1 — a rare lysosomal storage disorder — currently in the GALILEO-3 Phase 3 registrational trial, with completed GALILEO-1 and GALILEO-2 studies providing two-year follow-up data on clinical efficacy and bone health markers. The company is also developing a Parkinson's disease gene therapy program and has stated intent to expand into forms of dementia and certain cardiovascular diseases, signaling a strategic broadening beyond its initial rare-disease focus.
The company is pre-revenue with no commercialized products; revenue generation will depend on successful regulatory approval and subsequent commercialization of its gene therapy candidates. To date, the company has been funded through a combination of private financing rounds and a March 2022 registered direct offering of American Depositary Shares ($26.1M), having previously listed on NASDAQ under the ticker FRLN before delisting and rebranding to Spur Therapeutics. The go-to-market motion is enterprise/field-sales oriented in the long term, advancing candidates through FDA regulatory pathways and targeting rare-disease patients through clinical research, with planned distribution via specialty channels upon approval. The customer base — once commercialized — will center on patients with Gaucher disease type 1 (primary) and Parkinson's disease (secondary), positioning the company in the orphan and large chronic-disease gene therapy segments respectively.
Freeline firmographics
Firmographics- Name
- Freeline
- Legal name
- Spur Therapeutics
- Website
- https://freeline.life
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Spur Therapeutics (formerly Freeline) is a clinical-stage UK biotech developing AAV-based single-dose gene therapies, with lead candidate FLT201 in Phase 3 for Gaucher disease type 1 and a pipeline extending into Parkinson's and other chronic conditions. The company is pre-revenue, targeting rare-disease and neurodegenerative patients upon regulatory approval.
- Ownership category
- akta.pro rank
Freeline industry classification
Industry- Product category
- Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)
Keywords
Where Freeline is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Freeline business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Gene Therapy Product Commercialization: Pre-revenue clinical-stage biotech. Developing gene therapy candidates (FLT201 for Gaucher disease, Parkinson's programs) that will generate revenue upon FDA approval and commercial launch. Currently funded through registered direct offerings and other corporate activities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Freeline product offering
Product offeringCore offering
Freeline (now Spur Therapeutics) is a clinical-stage biotechnology company developing transformative AAV-based gene therapies for systemic debilitating diseases. Its lead candidate, avigbagene parvec (FLT201), is an investigational AAV gene therapy for Gaucher disease type 1 currently advancing through the GALILEO-3 Phase 3 registrational trial. The company is also building a Parkinson's disease gene therapy program and expanding toward additional widespread conditions.
Product overview
Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotech developing gene therapies. The company's pipeline consists of avigbagene parvec (FLT201), an AAV gene therapy for Gaucher disease type 1 currently in Phase 3 registrational trials (GALILEO-3), and a Parkinson's Disease program focused on disease-modifying treatments. The company is expanding its gene therapy approach from rare diseases toward more widespread conditions including forms of Parkinson’s and dementia, and certain cardiovascular diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- avigbagene parvec (FLT201)
Quantifiable outcome
- Two-year follow-up data demonstrating avigbagene parvec (FLT201) efficacy and impact on bone health markers in adults with Gaucher disease type 1 from GALILEO-1 and GALILEO-2 trials
Companies that use Freeline
Customer profileSegments2 records
Ideal customer profiles2 records
Freeline technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Freeline partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Freeline competitors and assessment
Company assessmentDirect peers
- Passage Bio: Clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases; comparable in scale, modality, and pipeline focus on AAV delivery for rare and neurological indications.
- BioMarin Pharmaceutical: Commercial-stage AAV gene therapy developer with Roctavian (valoctocogene roxaparvovec) for hemophilia A; directly comparable as a clinical-to-commercial AAV gene therapy company pursuing registrational approvals for rare diseases.
- uniQure: AAV gene therapy developer with a Phase 3 program (etranacogene dezaparvovec partnered with CSL Behring for hemophilia B); closely comparable as an AAV-focused company advancing through pivotal trials in rare monogenic diseases.
- REGENXBIO: Pure-play AAV gene therapy platform company with internal pipeline and licensing model; comparable as a technology-platform peer supplying and developing AAV-based therapeutics across rare and CNS indications.
- Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies primarily for CNS/neurological disorders including Parkinson's disease; directly comparable as a fellow AAV developer pursuing Parkinson's with disease-modifying ambition.
- Solid Biosciences: Clinical-stage AAV gene therapy developer focused on Duchenne muscular dystrophy and other rare muscle/CNS disorders; comparable as a clinical-stage AAV pure-play with similar scale and regulatory pathway focus.
- Lexeo Therapeutics: Clinical-stage AAV gene therapy company with programs in cardiac and CNS rare diseases; comparable as a recent-era AAV developer expanding beyond monogenic rare diseases into broader indications like cardiovascular.
- Taysha Gene Therapies: Clinical-stage AAV gene therapy company with a CNS-focused pipeline; comparable in modality, clinical stage, and rare/neurological disease focus to Spur Therapeutics.
Broad incumbents
- Sanofi (Genzyme): Through Genzyme, markets Cerezyme/imiglucerase — the dominant enzyme replacement therapy for Gaucher disease type 1; the established incumbent Spur would need to displace or convert patients from this franchise.
Emerging players
- Prevail Therapeutics (Eli Lilly): AAV-based gene therapy developer (now part of Eli Lilly) focused on GBA1-linked Parkinson's disease and other CNS/neurodegenerative disorders; directly overlaps with Spur's Parkinson's program targeting disease modification.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Freeline social profiles
Digital presenceFreeline financial estimates
Financial estimateRevenue estimate
Valuation estimate
Freeline leadership team
Management profileNumber of profiles
Profiles7 records
Freeline funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Freeline M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Freeline
What does Freeline do?
Freeline (now Spur Therapeutics) is a clinical-stage biotechnology company developing transformative AAV-based gene therapies for systemic debilitating diseases. Its lead candidate, avigbagene parvec (FLT201), is an investigational AAV gene therapy for Gaucher disease type 1 currently advancing through the GALILEO-3 Phase 3 registrational trial. The company is also building a Parkinson's disease gene therapy program and expanding toward additional widespread conditions.
Is Freeline a public or private company?
Freeline is a private company. It is classified as venture growth investor backed and is currently operating.
When was Freeline founded?
Freeline was founded in 2015. It employs 251 to 500 people.
Where is Freeline based?
Freeline is headquartered in Stevenage, United Kingdom, in the Europe region.
How does Freeline make money?
One revenue line is on record: gene Therapy Product Commercialization.
Who are Freeline's main competitors?
Direct peers on record are Passage Bio, BioMarin Pharmaceutical, uniQure, REGENXBIO, Voyager Therapeutics, Solid Biosciences, Lexeo Therapeutics and Taysha Gene Therapies. Sanofi (Genzyme) is listed as a broad incumbent. Prevail Therapeutics (Eli Lilly) is listed as an emerging player.
Does Freeline have an API?
No public API is recorded for Freeline.
What industry is Freeline in?
Freeline's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.